Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face

International Journal of STD and AIDS

Volumn 24, Issue 9, 2013, Pages 685-694

  Kadouch, J A ^a   van Rozelaar, L ^b   Karim, R B ^c   Hoekzema, R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Medical Laser Centre   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

AIDS; antiretroviral therapy; CART induced lipoatrophy; face; facial lipoatrophy; fillers; HIV; lipodystrophy; toxicity; treatment methods

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIRETROVIRUS AGENT; ARTECOLL; ARTEFILL; COLLAGEN; DIDANOSINE; EFAVIRENZ; FILLER; FOSAMPRENAVIR; GLITAZONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; HYALURONIC ACID; INDINAVIR; LEPTIN; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; PLACEBO; POLY(METHYL METHACRYLATE); POLYACRYLAMIDE; PROTEINASE INHIBITOR; RECOMBINANT METHIONYL LEPTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; TESAMORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOCYTE; ADIPOSE TISSUE; ADOLESCENT; ADULT; CHILD; CHOLESTEROL BLOOD LEVEL; COMBINATION ANTIRETROVIRAL THERAPY; COMBINATION ANTIRETROVIRAL THERAPY INDUCED LIPOATROPHY; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECCHYMOSIS; ESTHETIC SURGERY; FACE; FACE DISORDER; FACE LIPOATROPHY; FACE MUSCLE; FACE SURGERY; FEAR; FOLLOW UP; HEMATOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LEPTIN DEFICIENCY; LIPOATROPHY; LIPODYSTROPHY; META ANALYSIS (TOPIC); METABOLIC PARAMETERS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF CONCEPT; SELF ESTEEM; SOFT TISSUE; SUBCUTANEOUS TISSUE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

AIDS; ANTIRETROVIRAL THERAPY; CART-INDUCED LIPOATROPHY; FACE; FACIAL LIPOATROPHY; FILLERS; HIV; LIPODYSTROPHY; TOXICITY; TREATMENT METHODS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FACE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84887356624     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462412474539     Document Type: Review

References (138)

1. Garg A.Acquired and inherited lipodystrophies.N Engl J Med. 2004;350:1220.
2. Fiorenza CG,Chou SH,Mantzoros CS.Lipodystrophy: pathophysiology and advances in treatment.Nat Rev Endocrinol. 2011;7:137-50.
3. Burgoyne RW,Tan DH.Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.J Antimicrob Chemother. 2008;61:469-73.
4. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the DHHS panel on Antiretroviral guidelines for Adults and Adolescents- A Working Group of the Office of AIDS Research Advisory Council, December 2009. See http://AIDSinfo.nih.gov.
5. Soares FM,Costa IM.HIV-Associated facial lipoatrophy: from the advent to current knowledge.An Bras Dermatol. 2011;86:843-62.
6. Martinez E.Disorders of fat partitioning in treated HIV-infection.Best Pract Clin Endocrin Metabolism. 2011;25:415-27.
7. Peterson S,Martins CR,Cofrancesco J.Lipodystrophy in the patient with HIV: social, psychological, and treatment considerations.Aesthet Surg J. 2008;28:443-51.
8. Sattler FR.Pathogenesis and treatment of lipodystrophy: what clinicians need to know.Top HIV Med. 2008;16:127-33.
9. Caron-Debarle M,Lagathu C,Boccara F, et al.HIV-associated lipodystrophy: from fat injury to premature aging.Trends Mol Med. 2010;16:218-29.
10. Joly V,Flandre P,Meiffedy V, et al.Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: result of a substudy from a comparative trial.AIDS. 2002;16:2447.
11. Ribera E,Paradiñeiro JC,Curran A, et al.Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).HIV Clin Trials. 2008;9:407-17.
12. Mallal SA,John M,Moore CB, et al.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.AIDS. 2000;14:1309.
13. Côté HC.Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction.Curr Opin HIV AIDS. 2007;2:253-60.
14. Mallon PW,Unemori P,Sedwell R, et al.In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.J infect Dis. 2005;191:1686-96.
15. Mallon PW,Sedwell R,Rogers G, et al.Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.J Infect Dis. 2008;198:1794-803.
16. Moyle GJ,Sabin CA,Cartledge J, et al.A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoathrophy.AIDS. 2006;20:2043.
17. Arpadi SM,Bethel J,Horlick M, et al.Longitudinal changes in regional fat content in HIV-infected children and adolescents.AIDS. 2009;23:1501-9.
18. Alam N,Cortina-Borja M,Goetghebuer T, et al.Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.J Acquir Immune Defic Syndr. 2012;59:314-24.
19. James J,Carruthers A,Carruthers J.HIV-associated facial lipodystrophy.Dermatol Surg. 2002;28:979-86.
20. Oette M,Juretzko P,Kroidl A, et al.Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients.AIDS Patient Care STDS. 2002;16:413.
21. Ammassari A,Antinori A,Cozzi-Lepri A, et al.Relationship between HAART adherence and adipose tissue alterations.J Acquir Immune Defic Syndr. 2002;31:S140.
22. Corless IB,Kirksey KM,Kemppainen J, et al.Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS.AIDS Patient Care STDS. 2005;19:577-86.
23. Karim RB,de Lint CA,van Galen SR, et al.Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.Aesthet Plast Surg. 2008;32:873-8.
24. Nelson L,Stewart KJ.Psychological morbidity and facial volume in HIV lipodystrophy: quantification of treatment outcome.J Plast Reconstr Aesthet Surg. 2012;65:439-47.
25. De Santis G,Pignatti M,Baccarani A, et al.Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: a 5-year follow-up.Plast Reconstr Surg. 2012;129:101-9.
26. Lafeuillade A,Clumeck N,Mallolas J, et al.Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trivizir versus continued HAART: the Trzal study.HIV Clin Trials. 2003;4:37.
27. John M,McKinnon EJ,James IR, et al.Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-positive patients.J Acquir Immune Defic Syndr. 2003;33:29.
28. Raboud JM,Diong C,Carr A, et al.A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.HIV Clin Trials. 2010;11:39-50.
29. Sivakumar T,Mechanic O,Fehmie DA,Paul B.Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.HIV Med. 2011;12:453-62.
30. Dhillon S.Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs. 2011;71:1071-91.
31. Jones D.HIV facial lipoatrophy: causes and treatment.Dermatol Surg. 2005;2:1519-29.
32. Sturm LP,Cooter RD,Mutimer KL, et al.A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.AIDS Patient Care STDS. 2009;23:699-714.
33. Guaraldi G,Fontdevila J,Christensen LH, et al.Surgical correction of HIV-associated facial lipoatrophy.AIDS. 2011;25:1-12.
34. Jones DH.Treatment of HIV associated facial lipoatrophy: 2012 update.Dermatol Surg. 2012;38:1206-7.
35. Moyle G,Baldwin C,Mandalia S, et al.Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort.J Acquir Immune Defic Syndr. 2001;28:399.
36. Fisac C,Fumero E,Crespo M, et al.Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.AIDS. 2005;19:917.
37. Oral EA,Chan JL.Rationale for leptin-replacement therapy for severe lipodystrophy.Endocr Pract. 2010;16:324-33.
38. Veloso S,Escoté X,Ceperuelo-Mallafré V, et al.Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy.Cytokine. 2012;58:253-60.
39. Nagy GS,Tsiodras S,Martin LD, et al.Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin.Clin Infect Dis. 2003;36:795.
40. Chan JL,Lutz K,Cochran E, et al.Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.Endocr Pract. 2011;17:922-32.
41. Lee JH,Chan JL,Sourlas E, et al.Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.J Clin Endocrin Metab. 2006;91:2605.
42. Mantzaros CS,Magkos F,Brinkoetter M, et al.Leptin in human physiology and pathophysiology.Am J Physiol Endocrinol Metab. 2011;301:E567-84.
43. Walker UA,Auclair M,Lebrecht D, et al.Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions.Antivir Ther. 2006;11:25-34.
44. McComsey GA,Walker UA,Budhathoki CB, et al.Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.AIDS. 2010;24:2507-15.
45. Sutinen J,Walker UA,Sevastianova K, et al.Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.Antvir Ther. 2007;12:97-105.
46. Arioglu E,Duncan-Morin J,Sebring N, et al.Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.Ann Intern Med. 2000;133:263.
47. Tungsiripat M,Bejjani DE,Rizk N, et al.Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regiments.AIDS. 2010;24:1291-8.
48. Koutkia P,Canavan B,Brue J, et al.Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.JAMA. 2004;292:210-8.
49. Spooner LM,Olin JL.Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother. 2012;46:240-7.
50. Bedimo R.Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.HIV AIDS (Auckl). 2011;3:69-79.
51. The American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank Statistics. See http://www.surgery.org/sites/default/files/2009stats.pdf (last checked June 2012).
52. Broder KW,Cohen SR.An overview of permanent and semipermanent fillers.Plast Reconstr Surg. 2006;118:7S-14S.
53. DeLorenzi C,Weinberg M,Solish N,Swift A.The long-term efficacy and safety of a subcutaneously injected large-particle stabilized hyaluronic acid-based gel of nonanimal origin in esthetic facial contouring.Dermatol Surg. 2009;35:313-21.
54. Gooderham M,Solish N.Use of hyaluronic acid for soft tissue augmentation of HIV associated facial lipodystrophy.Dermatol Surg. 2005;31:104-8.
55. Skeie L,Brugge H,Negaard A,Bergersen BM.Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study.HIV Med. 2010;11:170-7.
56. Bechera FG,Gambichler T,Brockmeyer NH, et al.Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.Dermatology. 2008;217:244-9.
57. Bugge H,Negaard A,Skeie L,Bergersen B.Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients.HIV Med. 2007;8:475-82.
58. Pignatti M,Pedone A,Baccarani A, et al.High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.Aesthet Plast Surg. 2012;36:180-5.
59. Hanke CW,Redbord KP.Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.J Drugs Dermatol. 2007;6:123-8.
60. Carey D,Baker D,Petoumenos K, et al.Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.HIV Med. 2009;10:163-72.
61. Levy RM,Redbord KP,Hanke CW.Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.J Am Acad Dermatol. 2008;59:923-33.
62. Kavouni A,Catalan J,Brown S, et al.The face of HIV and AIDS: can we erase the stigma?.AIDS Care. 2008;20:485-7.
63. Mest DR,Humble GM.Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.Dermatol Surg. 2009;35:350-9.
64. El-Beyrouty C,Huang V,Darnold CJ,Clay PG.Poly-L-lactic acid for facial lipoatrophy in HIV.Ann Pharmacother. 2006;40:1602-6.
65. Mest D,Humble G.Review and evaluation of treatment procedures using injectable poly-L-lactic acid in the treatment of human immunodeficiency virus-associated facial lipoatrophy.J Clin Aesthet Dermatol. 2010;3:43-9.
66. Tagle JM,Macchetto PC,Durán Páramo RM.Clinical performance of a dermal filler containing natural glycolic acid and a polylactic acid polymer: results of a clinical trial in human immunodeficiency virus subjects with facial lipoatrophy.J Clin Aesthet Dermatol. 2010;3:42-7.
67. Gunatillake PA,Adhikari R.Biodegradable synthetic polymers for tissue engineering.Eur Cell Mater. 2003;5:1-16.
68. Gogolewski S,Jovanovic M,Perren SM, et al.Tissue response and in-vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybutyrate-co-3- hydroxyvalerate) (PHB/VA).J Biomed Mater Res. 1993;27:1135-48.
69. Lacombe V.Sculptra: a stimulatory filler.Facial Plast Surg. 2009;25:95-9.
70. Valantin MA,Aubron-Olivier C,Ghosn J, et al.Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.AIDS. 2003;17:2471-7.
71. Kates LC,Fitzgerald R.Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.Aesthet Surg J. 2008;28:397-403.
72. Bassichis B,Blick G,Conant M, et al.Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES).Dermatol Surg. 2012;38:1193-205.
73. Moyle GJ,Brown S,Lysakova L,Barton SE.Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.HIV Med. 2006;7:181-5.
74. Narins. Minimizing adverse events with PLLA.Dermatol Surg. 2008;34:S100-4.
75. Stewart DB,Morganroth GS,Mooney MA, et al.Management of visible granulomas.Opthal, Plast Reconstr Surg. 2007;23:298-301.
76. Mest DR,Humble G.Safety and Efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience.Dermatol Surg. 2006;32:1336-45.
77. Burgess C.The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.J Drugs Dermatol. 2011;10:1001-6.
78. Silvers SL,Eviatar JA,Echavez MI,Pappas AL.Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.Plast Reconstr Surg. 2006;188:34-45S.
79. Comite SL,Liu JF,Balasubramanian S,Christian MA.Treatment of HIV associated facial lipoatrophy with Radiance FN™ (Radiesse™).Dermatol Online J. 2004;10:2.
80. Carruthers A,Liebeskind M,Carruthers J,Forster BB.Radiographic and computed tomographic studies of Calcium Hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds.Dermatol Surg. 2008;34S1:S78-84.
81. Carruthers A,Carruthers J.Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus.Dermatol Surg. 2008;31:1486-99.
82. Jacovella PF.Use of calcium hydroxylapatite (Radiesse) for facial augmentation.Clin Interv Aging. 2008;3:161-74.
83. Alam M,Havey J,Pace N,Pongprutthipan M,Yoo S.Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions.J Am Acad Dermatol. 2011;65:92-6.
84. Jones DH.Midface volumizing with calcium hydroxylapatite.J Drugs Dermatol. 2012;11:31-2.
85. Tzikas TL.A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation.Dermatol Surg. 2008;34:S9-15.
86. Jacovella PF.Calcium hydroxylapatite facial filler (Radiesse): indications, technique, and results.Clin Plast Surg. 2006;33:511-23.
87. Jansen DA,Graivier MH.Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation.Plast Reconstr Surg. 2006;118:22S-30S.
88. Patrick T.Polyacrylamide gel in cosmetic procedures: experience with Aquamid.Semin Cutan Med Surg. 2004;23:233-5.
89. de Cássia Novaes W,Berg A.Experiences with a new nonbiodegradable hydrogel (Aquamid): a pilot study.Aesthetic Plast Surg. 2003;27:376-80.
90. Bello G,Jackson IT,Keskin M, et al.The use of polyacrylamide gel in soft-tissue augmentation: an experimental assessment.Plast Reconstr Surg. 2007;119:1326-36.
91. Mansor S,Breiting VB,Dahlstrom K, et al.Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.Aesthetic Plast Surg. 2011;35:709-16.
92. Rauso R,Freda N,Parlato V, et al.Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up.Dermatol Surg. 2011;37:1584-9.
93. Negredo E,Puig J,Aldea D, et al.Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.AIDS Res Hum Retroviruses. 2009;25:451-5.
94. Mole B,Gillaizeau F,Carbonnel E, et al.Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.AIDS Res Hum Retroviruses. 2012;28:251-8.
95. Cheng NX,Xu SL,Deng H, et al.Migration of implants: a problem with injectable polyacrylamide gel in aesthetic plastic surgery.Aesth Plast Surg. 2006;30:215-25.
96. Alijotas-Reig J,Garcia-Gimenez V,Miró-Mur F,Vilardell-Tarrés M.Delayed immune-mediated adverse effects related to polyacrylamide dermal fillers: clinical findings, management, and follow-up.Dermatol Surg. 2009;35:360-6.
97. Ono S,Ogawa R,Hyakusoku H.Complications after polyacrylamide hydrogel injection for soft-tissue augmentation.Plast Reconstr Surg. 2010;126:1349-57.
98. Colombo G,Caregnato P,Stifanese R,Ferrando G.Destructive granulomatous reaction to polyacrylamide lip injection: solution for a complex case.Aesthet Plast Surg. 2011;35:662-5.
99. Unukovych D,Khrapach V,Wickman M, et al.Polyacrylamide gel injections for breast augmentation: management of complications in 106 patients, a multicenter study.World J Surg. 2012;36:695-701.
100. Xu C,Cao M,Bao B, et al.Tissue degeneration 7 years after breast augmentation with injected polyacrylamide hydrogel (PAAG).Aesthet Plast Surg. 2012;36:160-2.
101. Pacini S,Ruggiero M,Cammarota N, et al.Bio-Alcamid, a novel prosthetic polymer, does not interfere with morphological and functional characteristics of human skin fibroblasts.Plast Reconstr Surg. 2003;111:489-91.
102. Ramires PA,Miccoli MA,Panzarini E, et al.In vitro and in vivo biocompatibility evaluation of a polyalkylimide hydrogel for soft tissue augmentation.J Biomed Mater Res B Appl Biomater. 2005;72:230-8.
103. Ramon Y,Fodor L,Ullman Y.Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.Dermatology. 2007;214:151-4.
104. Loutfy MR,Brunetta J,Kovacs C, et al.Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy.HIV Clin Trials. 2011;12:323-32.
105. Schelke L,van den Elzen H,Canninga M,Neumann M.Complications after treatment with polyalkylimide.Dermatol Surg. 2009;35:1625-8.
106. Lahiri A,Waters R.Experience with Bio-Alcamid, a new soft tissue endoprothesis.J Plast Reconstr Aesthet Surg. 2007;60:663-7.
107. Karim R,Hage J,Van Rozelaar L, et al.Complications of Polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases.J Plast Reconstr Aesth Surg. 2006;:1409-14.
108. Goldan O,Georgiou I,Grabov-Nardini G, et al.Early and late complications after a nonabsorbable hydrogel polymer injection: a series of 14 patients and novel management.Dermatol Surg. 2007;33:S199-206.
109. Jones DH,Carruthers A,Fitzgerald R, et al.Late-appearing abscesses after injections of nonabsorbable hydrogel polymer for HIV-associated facial lipoatrophy.Dermatol Surg. 2007;33:S193-8.
110. Akrish S,Dayan D,Taicher S, et al.Foreign body granulomas after injection of Bio-Alcamid for lip augmentation.Am J Otolaryngol. 2009;356-359:.
111. Ross A,Malhotra R.Long-term orbitofacial complications of polyalkylimide 4% (Bio-Alcamid).Opthal Plast Reconstr Surg. 2009;25:394-7.
112. Nelson L,Stewart KJ.Early and late complications of polyalkylimide gel (Bio-Alcamid)®.J Plast Reconstr Aesthet Surg. 2011;64:401-4.
113. Warde M,Gragnani A,Gomes H, et al.The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.Int J STD AIDS. 2011;22:596-9.
114. Orsi AT,Miranda AE,Souza AC, et al.Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil.Int J Dermatol. 2011;50:1255-8.
115. Lemperle G,Hazan-Gaúthier N,Lemperle M.PMMA microspheres (Artecoll) for skin and soft-tissue augmentation. Part II: Clinical investigations.Plast Reconstr Surg. 1995;96:627-34.
116. Lemperle G,Romano JJ,Busso M.Soft tissue augmentation with artecoll: 10-year history, indications, techniques and complications.Dermatol Surg. 2003;29:573-87.
117. Bagal A,Dahiya R,Tsai V,Adamson PA.Clinical experience with polymethylmethacrylate microspheres (Artecoll) for soft-tissue augmentation: a retrospective review.Arch Facial Plast Surg. 2007;9:275-80.
118. Stegman SJ.Injectable collagen.Plast Reconstr Surg. 1987;80:866.
119. Lemperle G,Knapp TR,Sadick NS,Lemperle SM.ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.Aesthetic Plast Surg. 2010;34:264-72.
120. Lemperle G,Gauthier-Hazan N,Lemperle M.PMMA-Microspheres (Artecoll) for long-lasting correction of wrinkles: refinements and statistical results.Aesthetic Plast Surg. 1998;22:356-65.
121. Lemperle G.Complications from artecoll are treatable.Aesthet Surg J. 2003;23:469-70.
122. Lemperle G,de Fazio S,Nicolau P.ArteFill: a third-generation permanent dermal filler and tissue stimulator.Clin Plast Surg. 2006;33:551-65.
123. Lemperle G,Gauthier-Hazan N,Wolters M, et al.Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes.Plast Reconstr Surg. 2009;123:1842-63.
124. Prather CL,Jones DH.Liquid injectable silicone for soft tissue augmentation.Dermatol Ther. 2006;19:159-68.
125. Rapaport MJ,Vinnik C,Zarem H.Injectable silicone: cause of facial nodules, cellulitis, ulceration and migration.Aesth Plast Surg. 1996;20:267-76.
126. Duffy DM.The silicone conundrum. A battle of anecdotes.Dermatol Surg. 2002;28:590-4.
127. Chasan PE.The history of injactable silicone fluids for soft-tissue augmentation.Plast Reconstr Surg. 2007;120:2034-40.
128. Orentreich DS.Liquid injectable silicone: techniques for soft tissue augmentation.Clin Plast Surg. 2000;27:595-612.
129. Benedetto AV,Lewis AT.Injecting 1000 centistoke liquid silicone with ease and precision.Dermatol Surg. 2003;29:211-4.
130. Orentreich D,Leone AS.A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.Dermatol Surg. 2004;30:548-51.
131. Jones DH,Carruthers A,Orentreich D, et al.Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.Dermatol Surg. 2004;30:1279-86.
132. JonesD. A report of 135 patients with 5 year and beyond follow up after treatment with highly purified liquid injectable silicone (LIS) for HIV associated facial lipoatrophy (HIV FLA). American Society for Dermatologic Surgery Annual Meeting. Chicago, IL, 24 October 2010.
133. Duffy DM.Liquid silicone for soft tissue augmentation.Dermatol Surg. 2005;31:1530-41.
134. Wolfort FG,Cetrulo CL,Nevarre DR.Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use.Plast Reconstr Surg. 1999;104:1814-20.
135. Rauso R,Curinga G,Santillo V, et al.Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.J Craniofac Surg. 2011;22:1684-8.
136. Uzzan C,Boccara D,Lacheré A, et al.Treatment of facial lipoatrophy by lipofilling in HIV infected patients: Retrospective study on 317 patients on 9 years.Ann Chir Plast Esthet. 2012;57:210-6.
137. Talmor M,Hoffman LA,LaTrenta GS.Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction.Ann Plast Surg. 2002;49:11.
138. Bergersen BM,Sandvik L,Ellingsen I,Bruun JN.Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.HIV Med. 2005;6:260-7.